Amneal Pharmaceuticals, Net Worth
Amneal Pharmaceuticals, Net Worth Breakdown | AMRX |
Amneal Pharmaceuticals, Net Worth Analysis
Amneal Pharmaceuticals,'s net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Amneal Pharmaceuticals,'s financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Amneal Pharmaceuticals,'s overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Amneal Pharmaceuticals,'s net worth analysis. One common approach is to calculate Amneal Pharmaceuticals,'s market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Amneal Pharmaceuticals,'s stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Amneal Pharmaceuticals,'s net worth. This approach calculates the present value of Amneal Pharmaceuticals,'s future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Amneal Pharmaceuticals,'s cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Amneal Pharmaceuticals,'s net worth. This involves comparing Amneal Pharmaceuticals,'s financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Amneal Pharmaceuticals,'s net worth relative to its peers.
Enterprise Value |
|
To determine if Amneal Pharmaceuticals, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Amneal Pharmaceuticals,'s net worth research are outlined below:
| Amneal Pharmaceuticals, generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 2.39 B. Net Loss for the year was (48.72 M) with profit before overhead, payroll, taxes, and interest of 791.46 M. | |
| Amneal Pharmaceuticals, has a strong financial position based on the latest SEC filings | |
| About 53.0% of the company shares are held by company insiders | |
| Latest headline from simplywall.st: Senior VP Of Amneal Pharmaceuticals Sold 76 percent Of Their Shares |
Amneal Pharmaceuticals, Quarterly Good Will |
|
Amneal Pharmaceuticals, uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Amneal Pharmaceuticals, Class. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Amneal Pharmaceuticals,'s previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 3rd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Amneal Pharmaceuticals,'s Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Amneal Pharmaceuticals, is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Amneal Pharmaceuticals, Class backward and forwards among themselves. Amneal Pharmaceuticals,'s institutional investor refers to the entity that pools money to purchase Amneal Pharmaceuticals,'s securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Nuveen Asset Management, Llc | 2024-06-30 | 2.5 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.1 M | Blackbarn Capital Partners Lp | 2024-06-30 | 2 M | Fosun International Ltd | 2024-09-30 | 1.7 M | Northern Trust Corp | 2024-09-30 | 1.6 M | Hennessy Advisors, Inc. | 2024-09-30 | 1.6 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.4 M | Goldman Sachs Group Inc | 2024-06-30 | 1.4 M | Woodline Partners Lp | 2024-06-30 | 1.3 M | Ubs Group Ag | 2024-06-30 | 21.8 M | Vanguard Group Inc | 2024-09-30 | 14.6 M |
Follow Amneal Pharmaceuticals,'s market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.88 B.Market Cap |
|
Project Amneal Pharmaceuticals,'s profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.04) | (0.04) | |
| Return On Capital Employed | 0.08 | 0.12 | |
| Return On Assets | (0.02) | (0.02) | |
| Return On Equity | (4.25) | (4.03) |
When accessing Amneal Pharmaceuticals,'s net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Amneal Pharmaceuticals,'s profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Amneal Pharmaceuticals,'s profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Amneal Pharmaceuticals,'s accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Amneal Pharmaceuticals, Class. Check Amneal Pharmaceuticals,'s Beneish M Score to see the likelihood of Amneal Pharmaceuticals,'s management manipulating its earnings.
Evaluate Amneal Pharmaceuticals,'s management efficiency
Amneal Pharmaceuticals, has return on total asset (ROA) of 0.0594 % which means that it generated a profit of $0.0594 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8577) %, meaning that it created substantial loss on money invested by shareholders. Amneal Pharmaceuticals,'s management efficiency ratios could be used to measure how well Amneal Pharmaceuticals, manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.12 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (0.04). At this time, Amneal Pharmaceuticals,'s Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 933.3 M in 2024, whereas Total Assets are likely to drop slightly above 3.2 B in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.35 | 0.33 | |
| Tangible Book Value Per Share | (8.11) | (8.51) | |
| Enterprise Value Over EBITDA | 7.44 | 7.82 | |
| Price Book Value Ratio | 54.05 | 56.75 | |
| Enterprise Value Multiple | 7.44 | 7.82 | |
| Price Fair Value | 54.05 | 56.75 | |
| Enterprise Value | 3.7 B | 4.4 B |
The strategic initiatives led by Amneal Pharmaceuticals,'s management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 1.9289 | Revenue 2.7 B | Quarterly Revenue Growth 0.133 | Revenue Per Share 9.16 | Return On Equity (1.86) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Amneal Pharmaceuticals, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Amneal Pharmaceuticals,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Amneal Pharmaceuticals, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Amneal Pharmaceuticals, Corporate Filings
F4 | 22nd of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 8th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Amneal Pharmaceuticals, Earnings per Share Projection vs Actual
Already Invested in Amneal Pharmaceuticals, Class?
The danger of trading Amneal Pharmaceuticals, Class is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Amneal Pharmaceuticals, is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Amneal Pharmaceuticals,. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Amneal Pharmaceuticals, is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Amneal Stock Analysis
When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.